MedTrace Logo

HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)

NCT06210334 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2024-02-20

No results posted yet for this study

Summary

To estimate the safety and efficacy of hepatic artery infusion chemotherapy (HAIC) combine Tislelizumab and Lenvatinib (HAI-TIS-LEN) in the Treatment of hepatocellular carcinoma (HCC) with type IV(Vp4) portal vein tumor thrombus (PVTT).

Conditions

  • Hepatocellular Carcinoma With PVTT

Interventions

DRUG

Tislelizumab

Tislelizumab 200mg, iv, d3, q3w

DRUG

Lenvatinib

Lenvatinib 8mg (\<60kg) or 12mg (≥60kg), po, qd

Sponsors & Collaborators

  • Li Xiao Wei

    lead OTHER

Principal Investigators

  • Jian Zhai, MM · Eastern Hepatobiliary Surgery Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-31
Primary Completion
2025-07-31
Completion
2026-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06210334 on ClinicalTrials.gov